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Ch-HU1 cells [ 1 I. These neuronal-like cells have been used widely in studying cellular signalling pathways because they express several G-proteinlinked receptors and a variety of heterotrimeric, plasma membrane-associated G-proteins, including G,, G,2, G,3, G,,,, and at least two variants of G,, 121, which allow the conversion of extracellular signals into intracellular responses.
A range of studies have examined the specificity of receptor and G-protein coupling in NG108-15 cells (see [2] for review). Many of these have employed G-protein a subunit-specific antisera raised against the C-terminal decapeptides of the various G-protein a subunits to attempt to interfere with receptor activation of the G-proteins, as both genetic and biochemical evidence has implicated a key role for this region in contacts between G-protein and receptors [3-51. Using such antisera to uncouple the 8-opioid receptor from its associated G-protein, McKenzie and Milligan [6] showed that receptor-mediated inhibition of adenylyl cyclase occurred via G,2, while McFadzean et al. [7] have demonstrated a specific role for Go in transducing noradrenaline-induced inhibition of Caz + currents. Homologous desensitization is the process whereby exposure of a cell or tissue to an agonist results in a decreased response to that agonist. This effect is often produced by a modification to, or physical loss of, the receptor to which the agonist binds. By contrast, heterologous desensitization is defined when exposure to an agonist for one receptor results also in a decreased response to agonists which activate other receptors. Appropriate loci for the development of heterologous forms of desensitization would be a functional or physical loss of some post-receptor component(s) of a signal transduction cascade. We have recently demonstrated that treatment of rat white adipocytes maintained in Abbreviation used: NECA, 5'-(N-ethy1)carboxamidoadenosine.
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tissue culture with agonists that cause a substantial reduction in membrane levels of the 'G,-like' G-proteins results in heterologous desensitization of all antilipolytic receptors, while only homologous desensitization is noted for agonists at receptors which do not cause a downregulation of these G-proteins 181. It strating that it is not a consequence simply of cellular redistribution of this polypeptide. Furthermore, the loss of G , a is independent of the generation of cyclic AMP [9] , revealing that the effect, while requiring receptor activation, is unlikely to be produced by a second messenger-activated kinase. Dose-response curves to iloprost and time courses of downregulation of both the prostanoid receptor and G , a are indistinguishable [lo] . This concurrence suggests the possibility of co-ordinated downregulation of these two polypeptides. Furthermore, by quantitating the loss of these polypeptides using a combination of ligand binding assays and quantitative immunoblotting, we observed a ratio of some 1 receptor:8G,a at every concentration of iloprost tested, indicating that the percentage occupancy of the IP prostanoid receptor by agonist did not alter the ratio of receptor and G,a downregulated [lo] . However, following exposure to iloprost, the remaining prostanoid receptor and G,a could be shown to remain coupled, as addition of guanine nucleotides was still able to reduce the affinity of agonist binding to the receptor [lo] .
The mechanism of iloprost-induced reduction in cellular levels of G,a appears not to involve either transcriptional or translational control to any measurable degree [9] and, while it awaits formal demonstration, is likely to result from an agonistinduced enhancement of turnover of the protein. This is clearly the case for the agonist-induced cellular reduction in levels of the phosphoinositidase C linked G-protein G,a/G,,a which we have noted following addition to the cholinergic agonist carbachol to Chinese hamster ovary cells transfected to express high levels of the human muscarinic M1 acetylcholine receptor (F. M. Mitchell, N. Ruckley and G. Milligan clearly preceded downregulation of this polypeptide, consistent with the downregulation being dependent on prior ADP-ribosylation [ 111. As G,a has been suggested to be a substrate for endogenous (mono) ADP-ribosyl transferases [ 15-171, and prolonged treatment with nicotinamide, which inhibits endogenous ADP-ribosyl transferase activity, has been reported to result in a twofold increase in plasma membrane-associated G , a [ 171, it is clearly possible that ADP-ribosylation will alter the turnover of G,a. Further studies to assess this possibility are both warranted and required.
While prolonged iloprost treatment results in downregulation of G , a in NG108-15 cells, by contrast, similar treatments of the cells either with the adenosine A2 receptor agonist, 5'-(Nethy1)carboxamido-adenosine (NECA), or with secretin causes no measurable alteration [ 181. As noted above, generation of cyclic AMP is not required for the prostanoid receptor-mediated loss of G,a, and thus the lack of effect of agonists at these two other receptors which activate adenylyl cyclase is unlikely to be due to the lower activation of adenylyl cyclase they produce in comparison to the prostanoid receptor. We reasoned that it might, however, reflect the levels of expression of these receptors. (some 1.5-2.5% of the measured levels of the IP prostanoid receptor). Thus, if G , a was downregulated by activation of this receptor with a similar stoichiometry to that observed following IP prostanoid receptor activation [lo], then we might anticipate a loss of only approximately 1-2% of the cellular G,a. As noted above, this would be impossible to detect using immunoblotting techniques. The number of A2 adenosine receptors present remains unknown, as the commonly used ligand ['HINECA has been shown to bind to the nucleoside transporter as well as to the A2 adenosine receptor [21] .
In an attempt to examine whether iloprostinduced downregulation of G,a is a unique feature of the IP prostanoid receptor or whether other G,-linked receptors would produce a similar effect if expressed in high levels in NG 108-1 5 cells, we have recently transfected parental NG108-15 cells using the 'Lipofectin' reagent with a construct containing a human b2 adrenoceptor cDNA under the control of the pactin promoter in a plasmid (pJM16) [22] which also expresses the neomycin-resistance gene. Subsequently, geneticin-resistant clones were selected and expanded.
Previous studies in murine S49 lymphoma cells have shown that agonist stimulation of the endogenously expressed p2 adrenoceptor can cause a rapid reduction of membrane-associated G, a [23] . The outcome of this process, however, dif-fered markedly from that produced by prostanoid treatment of NG108-15 cells as in this case, the G-protein was simply redistributed from the membrane fraction to the cytosol, and this occurred very rapidly, with a half-time of a few minutes [23] .
T o date we have examined, in particular, two clones isolated from this transfection. Using saturation binding analyses with the P-adrenergic adrenoceptor does not produce detectable downregulation of G , a when the receptor is expressed at much lower levels. It will be intriguing to examine whether G-protein downregulation will depend in a linear fashion on levels of receptor expression. As dose-response curves indicate greater downregulation of G,a occurs with increasing receptor occupancy, this is likely to be so, but the idea will also be examined by selecting further clones which express varying levels of the receptor and by blocking differing proportions of the P2 adrenoceptor with irreversible antagonists.
In an attempt to examine the possibility that there may be separate receptor-specific 'pools' of G , a within the membrane of NG108-15 cells, PN22 cells were treated with isoprenaline and iloprost both separately and in concert. It was observed that dual agonist treatment caused a greater downregulation of C;, a than treatment with either isoprenaline or iloprost alone (Figure 2) . The downregulation of G, Q observed upon treatment with the combination of iloprost and isoprenaline was, however, less than additive. While further studies are required in this area, these observations suggest several possibilities. One of these is that there is a single pool of G,. The ability of the agonist-activated P2 adrenoceptors to promote further downregulation of G , a than that produced by the IP prostanoid receptor would then be a reflection that neither the IP prostanoid receptor nor the Pr adrenoceptor is expressed at sufficiently high levels to activate the entire C, population even when each individual receptor pool is maximally activated. More complex possibilities exist. For example, not all of the cellular G,a may be accessible to the agonist-activated receptors. Such accessibility would be likely to be dependent on membrane localization and may suggest either the existence of separate plasma membrane domains of G, a, potentially delineated by the molecular architecture of the cytoskeleton of the cell, or that a proportion of the cellular G , a is located in a membrane fraction other than the plasma membrane. As we have measured G , a levels in these Volume 21 
